Reports Q3 revenue $2.91M, consensus $2.13M. “Immunome (IMNM) continues to advance its pipeline,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “Topline data for the RINGSIDE Part B trial of AL102 is expected in the second half of 2025, and IND submissions for IM-1021 and IM-3050 are on track.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- IMNM Earnings this Week: How Will it Perform?
- Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Immunome initiated with an Overweight at Stephens
- Immunome initiated with an Overweight at Stephens on ‘seasoned leadership’
- Immunome Advances with Strategic Asset Acquisition and Agreement